Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 24 of 65 for:    HTLV

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00854581
Recruitment Status : Terminated (Investigator Decision)
First Posted : March 3, 2009
Results First Posted : January 6, 2015
Last Update Posted : April 17, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Juan C. Ramos, University of Miami

Tracking Information
First Submitted Date  ICMJE February 28, 2009
First Posted Date  ICMJE March 3, 2009
Results First Submitted Date December 22, 2014
Results First Posted Date January 6, 2015
Last Update Posted Date April 17, 2018
Study Start Date  ICMJE November 2007
Actual Primary Completion Date June 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 19, 2018)
  • Number of Patients Achieving Clinical Response to Protocol Therapy Who Lack IRF-4 and/or c-Rel Expression. [ Time Frame: Up to 12 months post-initiation of protocol therapy ]
    Number of patients achieving clinical response (complete response (CR) + partial response (PR)) who lack interferon regulatory factor 4 (IRF-4) or c-Rel biomarker expression. Treatment response was assessed according to the International Consensus Review's adult T-cell leukemia/lymphoma (ATLL) consensus report by Tsukasaki et al published in the Journal of Clinical Oncology (JCO) in 2009. For imaging, Cheson criteria was used to assess response:
    • Complete response (CR): Disappearance of all clinical, microscopic, and radiographic evidence of disease. All lymph nodes regressed to normal size (≤ 1.5 cm), and previously involved nodes that were 1.1 to 1.5 cm decreased to ≤ 1.0 cm. In addition, abnormally elevated peripheral blood absolute lymphocyte count (ALC) < 4 x 10^9 /L.
    • Partial response (PR): ≥ 50% reduction in measurable disease and abnormal lymphocyte count in peripheral blood.
    • CR or PR had to persist for a period of at least 4 weeks.
  • Presence of Minimal Residual Disease at 3 and 6 Months of Maintained Remission and at 1 Year Post Initiation of Therapy [ Time Frame: 3, 6 and 12 months. ]
    Number of participants achieving complete response (CR) with minimal residual disease at 3, 6 and 12 months post-initiation of protocol therapy. Treatment response was assessed according to the International Consensus Review's adult T-cell leukemia/lymphoma (ATLL) consensus report by Tsukasaki et al published in the Journal of Clinical Oncology (JCO) in 2009. For imaging, Cheson criteria was used to assess response:
    • Complete response (CR): Disappearance of all clinical, microscopic, and radiographic evidence of disease. All lymph nodes regressed to normal size (≤ 1.5 cm), and previously involved nodes that were 1.1 to 1.5 cm decreased to ≤ 1.0 cm. In addition, abnormally elevated peripheral blood absolute lymphocyte count (ALC) < 4 x 10^9 /L.
    • Partial response (PR): ≥ 50% reduction in measurable disease and abnormal lymphocyte count in peripheral blood.
    • CR or PR had to persist for a period of at least 4 weeks.
  • Expressions of c-Rel, IRF-4 and Other Molecular Events in Participants [ Time Frame: At time of relapse or disease progression, assessed up to 12 months ]
    Expressions of c-Rel, IRF-4 or other molecular events (p53, p16 mutations) including expansion of novel clones obtained at time of relapse will be compared to baseline data using paired t-test.
  • Number of Participants Exhibiting NF-kB Inhibition Upon Treatment With AZT in Vivo [ Time Frame: During 48 hours of first AZT therapy ]
    Number of patients exhibiting NF-kb inhibition upon treatment with AZT in vivo. Investigation of whether AZT functions as an inhibitor of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) in vivo by analyzing serially collected leukemic samples during the first 48 hours of treatment with AZT only. The investigators will report the number of participants exhibiting NF-kB inhibition upon treatment with AZT in vivo and correlate with response using two-sample t-test.
  • The Effect of Valproic Acid Therapy on Persistence of Clonal Disease in Patients Who Achieve Clinical Remission [ Time Frame: 3, 6 and 12 months. ]
    Number of participants achieving a molecular remission after starting valproic acid as evidenced by disappearance of T-cell clonality as measured by gene rearrangement studies using multiplex PCR
Original Primary Outcome Measures  ICMJE
 (submitted: February 28, 2009)
  • Association between the lack of IRF-4 and/or c-Rel and response
  • Presence of Minimal Residual Disease at 3 and 6 Months of Maintained Remission and at 1 Year Post Initiation of Therapy
  • Association between antiviral escape and expression of IRF-4, c-Rel, or other molecular events
  • Function of zidovudine as an inhibitor of NF-κB
  • Effect of valproic acid therapy on persistent clonal disease
Change History Complete list of historical versions of study NCT00854581 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 19, 2018)
  • Failure-free Survival (FFS) [ Time Frame: From date of treatment initiation until date of documented disease progression, relapse after response, or death from any cause, assessed up to 5 years ]
    Failure-free survival is the elapsed time from the date of initiation of study treatment until date of documented disease progression, relapse after response, or death from any cause. For patients alive and free of relapse or progression, follow-up time was censored at the last documented date of failure-free status.
  • Overall Survival [ Time Frame: From date of treatment initiation until date of death, assessed up to 5 years ]
    Overall survival (OS) is the elapsed time from the date of initiation of study treatment until date of death from any cause. In the absence of death, the follow-up was censored at date of last contact.
Original Secondary Outcome Measures  ICMJE
 (submitted: February 28, 2009)
Failure-free and overall survival
Current Other Outcome Measures  ICMJE Not Provided
Original Other Outcome Measures  ICMJE Not Provided
 
Descriptive Information
Brief Title  ICMJE Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
Official Title  ICMJE Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b
Brief Summary

RATIONALE: Human T-cell lymphotropic virus type 1 (HTLV-1) can cause cancer. Zidovudine is an antiviral drug that acts against the human T-cell lymphotropic virus type 1. Giving zidovudine, interferon alfa-2b, and PEG-interferon alfa-2b together may stimulate the immune system and slow down or keep the cancer cell from growing.

PURPOSE: This clinical trial is studying how well giving zidovudine together with interferon alfa-2b and PEG-interferon alfa-2b works in treating patients with human T-cell lymphotropic virus type 1-associated adult T-cell leukemia/lymphoma.

Detailed Description

OUTLINE: This is a multicenter study.

  • Induction therapy: Patients receive zidovudine IV twice daily on days 1-14, and recombinant interferon alfa-2b IV twice daily on days 3-14. Patients achieving clinical complete response (CR) proceed to part 1 maintenance therapy; patients achieving partial response (PR) receive another 7 days of zidovudine and recombinant interferon alfa-2b and then proceed to part 1 maintenance therapy.
  • Part 1 maintenance therapy: Patients receive oral zidovudine twice daily and PEG-interferon alfa-2b subcutaneously (SC) once weekly, beginning on day 14 or 21 and continue to day 60. Patients are evaluated after completion of part 1 maintenance therapy and proceed to part 2 maintenance therapy.
  • Part 2 maintenance therapy: Patients achieving CR with undetectable clonal disease proceed to group A; patients achieving CR with minimal residual disease (by PCR) or PR proceed to group B.

    • Group A: Patients receive oral zidovudine twice daily and PEG-interferon alfa-2b SC once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
    • Group B: Patients receive oral zidovudine twice daily and PEG-interferon alfa-2b SC once weekly for 12 weeks and undergo reevaluation. Patients in continued CR with minimal residual disease or stable PR receive oral valproic acid twice daily, PEG-interferon alfa-2b SC once weekly, and oral zidovudine twice daily for 6 months. At that point (month 9) patients with no detectable clonal disease continue their previous treatment, while patients with minimal residual disease receive PEG-interferon alfa-2b SC and oral zidovudine twice daily in the absence of disease progression or unacceptable toxicity.

Blood samples are collected at baseline, days 1 and 2, and months 3, 6, and 12 for protein, genomic DNA, and RNA analysis. Baseline molecular characteristics of the tumor and tumor response to treatment is assessed.

After completion of study treatment, patients are followed every 3 months for 1 year.

Study Type  ICMJE Interventional
Study Phase Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Lymphoma
  • Precancerous/Nonmalignant Condition
Intervention  ICMJE
  • Biological: PEG-interferon alfa-2b
    Administered subcutaneously.
    Other Name: PEG-IFN-alfa2b
  • Biological: Interferon alfa-2b
    Administered intravenously.
  • Drug: Valproic Acid
    Administered orally.
    Other Name: Depakene
  • Drug: Zidovudine
    Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
    Other Names:
    • Retrovir
    • AZT
Study Arms
  • Experimental: Induction (Up to Day 21)

    For one cycle, up to Day 21. All participants are enrolled to induction therapy phase, then move to the maintenance therapy phase if they achieve complete response (PR) or partial response (PR). Participants who achieve a clinical CR at Day 14 response assessment will go on to Part 1 maintenance therapy. Patients who achieve a PR will receive 7 more days of induction therapy and then go on to Part 1 Maintenance Therapy.:

    • Zidovudine:

      • Days 1-2: 1.5 grams intravenously (IV) twice daily
      • Days 3-21: 1.5 grams IV twice daily
    • Interferon alfa-2b (IFN):

      • 5 10 million units (mu) intravenously twice daily
    Interventions:
    • Biological: Interferon alfa-2b
    • Drug: Zidovudine
  • Experimental: Part 1 Maintenance (Up to Day 60)

    From Treatment Day 14 or 21 to start of Month 3 (Day 60). Study participants move on to Part 1 Maintenance Therapy only if they achieve complete response (CR) or partial response (PR) after induction therapy. Restaging and molecular evaluation of disease at start of Month 3:

    • Zidovudine: 600 mg orally twice daily in all phases of Maintenance Therapy
    • PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly
    • Participants then proceed to Part 2 maintenance.
    Interventions:
    • Biological: PEG-interferon alfa-2b
    • Drug: Zidovudine
  • Experimental: Part 2A Maintenance (Up to 12 Months)

    Participants achieving a CR with undetectable clonal disease. Participants will receive therapy for as long as response is maintained:

    • Zidovudine: 600 mg orally twice daily
    • PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly
    Interventions:
    • Biological: PEG-interferon alfa-2b
    • Drug: Zidovudine
  • Experimental: Part 2B Maintenance (Up to 12 Months)

    Participants achieving a CR with minimal residual disease (by multiplex PCR) or PR in Part 1:

    • Zidovudine: 600 mg or 300 mg orally twice daily, per protocol
    • PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly, per protocol
    • Valproic acid, 250 mg orally twice daily, per protocol
    Interventions:
    • Biological: PEG-interferon alfa-2b
    • Drug: Valproic Acid
    • Drug: Zidovudine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: October 16, 2012)
13
Original Estimated Enrollment  ICMJE
 (submitted: February 28, 2009)
35
Actual Study Completion Date November 2011
Actual Primary Completion Date June 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  • Any stage, histologically or cytological documented adult T-cell leukemia/lymphoma (ATLL), leukemic types only (smoldering, chronic or acute). See Appendix I for definitions of the clinical subtypes.
  • Patients who have received prior treatment, including zidovudine and/or IFN, are eligible, provided that zidovudine/IFN therapy did not result in progressive disease.
  • Documented HTLV-I infection: documentation may be serologic assay (ELISA, Western blot) and confirmed to be HTLV-I rather than HTLV-2 by differential Western blot (e.g., Genelabs Diagnostics HTLV Blot 2.4) or PCR.
  • Measurable or evaluable disease.
  • Age 18 or older.
  • Karnofsky performance status ≥ 50%.
  • Patients must have adequate end organ and bone marrow function as defined below:

    • Absolute neutrophil count ≥ 1,000 cells/mm3 and platelets ≥ 50,000 cells/mm3 unless cytopenias are secondary to ATLL.
    • Adequate hepatic function: (transaminase ≤ 7 times the upper limit of normal, total bilirubin < 2.0), unless secondary to hepatic infiltration with lymphoma. If the elevated bilirubin is felt to be secondary to Indinavir or Atazavinir therapy (anti-HIV medications), patients will be allowed to enroll on protocol if the total bilirubin is ≤ 3.5 mg/dl provided that the direct bilirubin is normal.
    • Creatinine < 2.0 unless due to lymphomatous infiltration.
  • Patients who are HIV+ are also eligible.
  • Females with childbearing potential must have a negative serum pregnancy test within 72 hours of entering into the study. Males and females must agree to use adequate birth control if conception is possible during the study. Women must avoid pregnancy and men avoid fathering children while in the study.
  • Able to give consent.
  • Patients already receiving erythropoietin or granulocyte-colony stimulating factor (G-CSF) are eligible.

Exclusion Criteria

  • Concurrent active malignancies, with the exception of in situ carcinoma of the cervix, non-metastatic, non-melanomatous skin cancer, or Kaposi's sarcoma not requiring systemic chemotherapy.
  • Grade 3 or 4 cardiac failure and/or ejection fraction < 50%.
  • Psychological, familial, sociological or geographical conditions that do not permit treatment and/or medical follow-up required to comply with the study protocol.
  • Patients may not be receiving any other investigational agents.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or breast-feeding women.
  • Hypersensitivity to interferon alpha-2b, peginterferon alpha-2b, zidovudine or any component of the formulation
  • Autoimmune or viral hepatitis or decompensated liver disease unless due to lymphoma.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00854581
Other Study ID Numbers  ICMJE 20070805
SCCC-2007055 ( Other Identifier: UM/Sylvester Comprehensive Cancer Center )
5P01CA128115-02 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Juan C. Ramos, University of Miami
Study Sponsor  ICMJE University of Miami
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Principal Investigator: Juan Carlos Ramos, MD University of Miami
PRS Account University of Miami
Verification Date December 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP